Enovis CORP (ENOV) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$17.85

From 52W high−45.61%

Volume2.19M

Market cap$1.04B

P/E (TTM)—

P/S (TTM)0.5x

Div yield—

Key dataSep 18, 2026

Open

$17.85

From 52W high

−45.61%

Volume

2.19M

Market cap

$1.04B

ValuationView details →

P/E (Fwd)

5.0x

EV/EBITDA

−3.3x

P/E (TTM)

—

RSI (14)

32.3

MomentumView details →

1D Return

+1.35%

YTD Return

−33.46%

SummaryUpdated Jul 1, 2026

Enovis Corporation (NYSE:ENOV) is a medical technology company that emerged from a strategic transformation of Colfax Corporation in 2022. The company operates as a focused medical device manufacturer serving the orthopedic and musculoskeletal treatment market worldwide. Enovis develops, manufactures, and distributes medical products used by orthopedic specialists, surgeons, physical therapists, and other healthcare professionals to treat patients with conditions ranging from degenerative diseases to sports injuries. The company has grown significantly through strategic acquisitions, most notably the Lima Corporate acquisition in 2024, which substantially expanded its reconstructive joint surgery capabilities.

Ask drillr about Enovis CORP →

ValuationView details →

P/E (Fwd)

5.0x

P/E (TTM)

—

EV/EBITDA

−3.3x

EV/Sales

1.0x

P/S (TTM)

0.5x

P/B (TTM)

0.7x

ProfitabilityView details →

Gross Margin

57.43%

Net Margin

−47.97%

EBITDA Margin

−31.22%

ROE (TTM)

−74.59%

ROA (TTM)

−29.25%

Asset Turnover

0.60x

GrowthView details →

Revenue YoY

+4.89%

EPS YoY

−36.14%

FCF YoY

+1710.80%

Revenue CAGR 3Y

+12.88%

EPS CAGR 3Y

−39.72%

EBITDA YoY

−51.86%

MomentumView details →

1D Return

+1.35%

YTD Return

−33.46%

1Y Return

−45.23%

RSI (14)

32.3

vs 50D SMA

−28.14%

vs 200D SMA

−26.95%

Capital & dividendView details →

Debt/Equity

0.93x

Current Ratio

1.98x

Quick Ratio

1.00x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.90

EPS Surprise

6.26%

Beats (12Q)

11/12

Next Q EPS Est

$0.77

Avg Surprise (4Q)

11.82%

Rev Surprise

0.16%

Financials snapshotView financials →

Revenue (TTM)

2.30B

Net Income (TTM)

−1.10B

Op. CF (TTM)

270.10M

Next earningsNov 5, 2026 →

Latest newsMore news →

Oliver Engert, Chief Administrative Officer of Enovis, purchased 7,598 shares of Enovis common stock in multiple transactions on September 2 and 3, 2026, totaling approximately $149,970.15d ago

Enovis Corp. CEO Damien McDonald purchased 13,035 shares of Enovis common stock on September 4, 2026, for approximately $249,620.15d ago

Similar companies

Power Solutions International, Inc.PSIX Babcock & Wilcox Enterprises, Inc.BW Graham CorporationGHM Chen Hsong Holdings Limited00057.HK Tennant CompanyTNC Shanghai Qingpu Fire-Fighting Equipment Co., Ltd.08115.HK Find similar companies →

Latest newsMore news →

Oliver Engert, Chief Administrative Officer of Enovis, purchased 7,598 shares of Enovis common stock in multiple transactions on September 2 and 3, 2026, totaling approximately $149,970.15d ago Enovis Corp. CEO Damien McDonald purchased 13,035 shares of Enovis common stock on September 4, 2026, for approximately $249,620.15d ago Enovis Corporation announced a binding offer to acquire eCential Robotics, a developer of surgical robotics and enabling technologies.19d ago